8-K: Dyadic International Reports Q1 2026 Progress and Financials

Dyadic International announced its first quarter 2026 financial results, highlighting significant progress in commercial partnerships and product development, alongside a notable increase in revenue.

Summary

• Dyadic International reported its financial results for the first quarter ended March 31, 2026.
• The company saw a substantial increase in total revenue, up 182.3% to $1,110,956 compared to $393,572 in Q1 2025.
• This revenue growth was driven by increases in research and development revenue, grant revenue, and license and milestone revenue.
• Net loss for the quarter was $1,954,683, or $(0.05) per share, an improvement from a net loss of $2,027,579, or $(0.07) per share, in the prior year's quarter.
• Cash, cash equivalents, restricted cash, and investment securities totaled approximately $6.6 million as of March 31, 2026.
• Significant corporate achievements include initial purchase orders for recombinant bovine transferrin, the commercial launch of AlbuFree DX, expanded collaborations with Fermbox Bio, and an OEM distribution agreement with IBT Bioservices.
• The company also advanced its biopharmaceutical programs supported by the Gates Foundation and CEPI.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong revenue growth and progress in strategic partnerships, though the company continues to operate at a net loss and its cash position has decreased.

Positives

• Total revenue increased by 182.3% to $1,110,956 for Q1 2026 compared to $393,572 for Q1 2025.
• Net loss decreased to $1,954,683 in Q1 2026 from $2,027,579 in Q1 2025.
• Basic and diluted net loss per common share improved to $(0.05) from $(0.07).
• Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry.
• Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals.
• Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I.
• Signed an OEM distribution agreement with IBT Bioservices for commercialization of recombinant products.
• Entered a development and commercialization agreement with BRIG Bio for recombinant bovine alpha-lactalbumin.

Negatives

• The company reported a net loss of $1,954,683 for the quarter.
• Cash, cash equivalents, restricted cash, and investment securities decreased to $6.6 million from $8.6 million at the end of the previous year.
• General and administrative expenses increased by 10.0% to $1,755,331, largely due to higher legal and accounting expenses.
• The company has a history of net losses, as noted in the forward-looking statements section.

Risks

• Market and regulatory acceptance of microbial protein production platforms and other technologies.
• Failure to commercialize microbial protein production platforms or other technologies.
• Competition, including from alternative technologies.
• The results of nonclinical studies and clinical trials.
• The company's capital needs.
• Changes in global economic and financial conditions.
• Reliance on information technology and dependence on third parties.
• Government regulations and environmental, social, and governance issues.

Future Outlook

The company is focused on transforming into a commercially driven organization, leveraging its proprietary microbial production platforms to bring animal-free recombinant proteins and enzymes to market. Management believes Dyadic is well-positioned to drive increasing product revenues as distribution partners broaden their reach and customer adoption expands.

Management Comments

• "Throughout 2025 and into early 2026, we remained focused on transforming Dyadic into a commercially driven organization by leveraging our proprietary microbial production platforms to bring animal-free recombinant proteins and enzymes to market, both independently and through strategic partnerships."
• "We are encouraged that these products are now moving through commercial sales channels and reaching customers, demonstrating the scalability of our technology platforms and the increasing market demand for our products."
• "As our distribution partners broaden their reach and customer adoption continues to expand across cell culture media and biomanufacturing applications supporting key growth markets such as cell and gene therapy, biologics manufacturing, and emerging markets such as cultivated meat, we believe Dyadic is well positioned to drive increasing product revenues."

Industry Context

StockSavvy.ai notes that Dyadic's Q1 2026 results reflect a strategic shift towards commercialization and partnership-driven revenue growth within the burgeoning biotechnology sector, particularly in areas like animal-free proteins for cell culture media and cultivated meat.

Related Party Transactions

• Interest expense related to convertible notes from related parties was $44,839 for the three months ended March 31, 2026.
• Accrued interest - related party on convertible notes was $41,800 as of March 31, 2026.
• Convertible notes, net of issuance costs - related party totaled $2,066,779 as of March 31, 2026.

Stakeholder Impact

• Shareholders may see potential for future growth driven by commercialization efforts and partnerships, but the company's continued net loss and reduced cash position present ongoing risks.
• Employees may benefit from the company's strategic shift towards commercialization, potentially leading to increased opportunities and stability.
• Customers in the cultivated meat, life sciences, and nutrition sectors stand to benefit from Dyadic's expanding portfolio of animal-free recombinant proteins and enzymes.
• Suppliers and creditors may be impacted by the company's cash management and ongoing operational expenses.

Next Steps

• Customer sampling activities for recombinant bovine alpha-lactalbumin expected to begin in mid-2026.
• Continued advancement of Gates Foundation-supported RSV and malaria antibody programs and the CEPI/FBS H5 avian influenza program.
• Broadening of partner-led and internal development programs focused on non-animal dairy proteins, food and nutrition enzymes, and baking/brewing enzyme applications.
• Continued scaling of production capabilities for multiple recombinant proteins and enzymes.
• Focus on increasing product availability through direct and partner-led commercialization efforts.

Key Dates

Recommendation

The company shows promising revenue growth and strategic progress, but the continued net loss and declining cash reserves warrant a cautious 'hold' recommendation. Further validation of commercial product success and improved cash flow will be critical for a more positive outlook.

Keywords

biotechnology, recombinant proteins, enzymes, financial results, Q1 2026, Dyadic International, AlbuFree DX, Fermbox Bio